Gland Pharma Limited has informed the Exchange about Options to purchase securities
GLAND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Gland Pharma's ESOP Compensation Committee, at its July 3, 2025 meeting, approved the grant of 15,347 stock options under ESOP 2025 to a single employee. Of these, 10,129 options carry an exercise price of ₹937.20 (50% of the NSE closing price on the grant date), while 5,218 options are priced at ₹1 (face value). The options will vest in three tranches: 34% in July 2026, 33% in July 2027, and the remaining 33% in July 2028, with a two-year exercise window after each vesting. The grant complies with SEBI's Share Based Employee Benefits and Sweat Equity Regulations, 2021.
This is a small, routine ESOP grant with negligible dilution risk. It signals continued use of stock-based incentives to retain key employees, but is unlikely to materially affect share price or shareholder value.